GSK to buy liver disease drug for as much as US$2 billion
[LONDON] GSK agreed to buy an experimental medicine to treat liver disease for as much as US$2 billion as the UK drugmaker seeks to shore up its pipeline of new medicines.
The treatment developed by Boston Pharmaceuticals is ready to enter the last stage of clinical trials and has the potential to become a best-in-class medicine to treat a form of fatty liver disease, GSK said Wednesday (May 14).
GSK shares have struggled amid concern over few potential blockbuster drugs in the pipeline compared with rivals, as some of its top medicines face patent expirations.
There is growing interest in liver disease, with both Eli Lilly and Novo Nordisk working on treating the condition. The liver can get damaged by a build-up of fat or from alcohol use, and there are few treatment options. Though the medicine GSK is buying could help with both, for now it's in development for damage caused by fat build-up – a disease known by the acronym MASH.
GSK said it will pay US$1.2 billion upfront for the drug, called efimosfermin, with potential for additional milestone payments totalling US$800 million.
Mid-stage trial data on efimosfermin showed a once a month injected dose rapidly reversed liver fibrosis and stopped it progressing. BLOOMBERG
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
3 hours ago
- Straits Times
Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says
Studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic optic neuropathy. PHOTO: REUTERS Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision loss, the European Medicines Agency's (EMA) safety committee said on June 6 . In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic optic neuropathy (Naion). This is the first time a regulator has confirmed the side effect. The condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Ozempic as well as in Novo's other diabetes drug Rybelsus, for at least one year, the regulator said. Naion is the second-most common cause of blindness due to optic nerve damage, after glaucoma. 'This has been reported as a potential risk for some time, so I think the clinical community is relatively aware of it. I don't see this as making any major difference to prescribing patterns,' said Barclays analyst Emily Field. US-listed shares of the Danish drugmaker were up nearly 2.5 per cent in early trading. The EMA, which started its review in December, has asked Novo to add Naion as a side effect of very rare frequency in the product information accompanying drugs that contain semaglutide. Novo said it would work with the EMA to update the labels, adding clinical trials and after-market studies did not suggest a reasonable possibility that the drugs caused the condition. The 'benefit-risk profile of semaglutide remains favourable', the company said in a statement. Novo has recently faced investor concerns that it is losing its first-mover advantage in the highly competitive obesity treatment market, leading the company to oust chief executive Lars Fruergaard Jorgensen in May. Wegovy and Eli Lilly's Zepbound currently dominate the weight-loss drug market, potentially worth about US$150 billion (S$193 billion) by the next decade. The EMA said several large studies in type-2 diabetes patients have suggested that use of Novo's drugs could raise the risk of developing Naion by twofold. A study of nearly 350,000 diabetes patients published in March showed that the risk of developing Naion more than doubled after two years of treatment with Ozempic, compared with patients taking medicines from other classes. The US Department of Health and Human Services did not immediately respond to a Reuters request for comment on whether the Food and Drug Administration was conducting a probe into the side effect. REUTERS Join ST's Telegram channel and get the latest breaking news delivered to you.
Straits Times
a day ago
- Straits Times
‘I felt a bullet': Palestinians recount deadly shooting near new Gaza aid site
Palestinians gather to collect what remains of relief supplies from the distribution centre of the US-backed Gaza Humanitarian Foundation, in Rafah on June 5, 2025. PHOTO: REUTERS KHAN YOUNIS, Gaza Strip – Hungry and desperate, they raced to secure just one box of food. After nearly three months without any aid entering the Gaza Strip, Palestinians had learned that an Israeli-backed aid site would open in Rafah. Israel promised an orderly system that would improve on the United Nations' efforts to distribute much-needed food to Palestinians in Gaza. Almost from the beginning, things went horribly wrong. On the night of May 31, Mr Mohammed Abdulal, 30, travelled 18 miles (29km) and joined thousands of people aggressively pushing their way forward, trying to reach the aid site. Israeli forces formed a wide perimeter around the site, which was overseen by US private security contractors. Suddenly, he heard a hail of gunfire, forcing people to flee in every direction, their terrified screams filling the night sky. A bullet ripped through Mr Abdulal's face, leaving him writhing in pain. 'I only took two steps before I felt a bullet tear into my right cheek and neck,' he said. 'I started shouting: 'People, I'm wounded. Help me.'' The rollout of the new aid effort over the past week by the Gaza Humanitarian Foundation, an effort conceived in Israel and endorsed by the United States, was supposed to help Palestinians get aid while keeping it out of the hands of Hamas. Instead, the effort, criticised by multiple aid groups and the United Nations, has devolved into scenes of chaos and death. The New York Times spoke to eight witnesses who described how attempting to reach the sites had become a life-threatening endeavour. The exact details of the deadly incidents remain murky. The Israeli military has acknowledged firing 'warning shots' toward Palestinians but has not taken responsibility for killing them. Multiple witnesses blamed Israeli forces for the deadly fire, which Gaza health officials say killed dozens of Palestinians trying to secure aid. The procedures for getting the new aid have often been unclear for Palestinians facing widespread hunger after Israel blocked food from entering Gaza. Many have sought to beat the huge crowds flooding the distribution sites by arriving as early as possible, often after walking long distances. While the UN relied on hundreds of distribution sites across Gaza, the Israeli-backed effort has only four, creating a bottleneck. Some Palestinians have tried to advance in the line by taking shortcuts to the aid sites outside the officially marked path, but people both on and off that path appeared to have come under fire, according to three of the witnesses. And people arriving early have been told to come back later by Israeli drones, but many have ignored those calls, worried that they will lose their spot in line, the witnesses said. Mr Mohammad Saqar, 43, said he had braved the shooting on June 1 by crouching low to the ground to avoid getting shot at, even as people were struck nearby. When he finally reached the site, he described a mad scramble as crowds rushed to grab the cardboard boxes of aid strewed in piles on the ground. 'It's like a race for food,' Mr Saqar said. 'Those who win the race get the aid.' Two days later, on June 3, a similar scene unfolded. Amid the crowd, Mr Walid Abdeen, 16, was shot in his upper body when gunfire erupted as he and thousands of other people approached the aid site. He suffered damage to his spleen and kidneys. 'We want food,' he said, struggling to speak after undergoing emergency surgery. 'I had to try to help my family.' Despite the violence, Israeli officials have argued that the new system enables food to reach Palestinians without benefiting Hamas. In contrast, many Palestinians say the United Nations – which governed the aid distribution process for most of the war – was far more humane with its approach, despite its imperfections. The UN and other prominent aid groups have boycotted the new distribution system, accusing Israel of using aid as a part of its military strategy. 'The people are desperate and hungry,' Mr Abdulal said. 'That's why they came.' The Gaza Humanitarian Foundation, which is spearheading the latest aid effort, has sought to downplay the significance of the shootings, saying it has provided more than 100,000 cardboard boxes of food 'without a single incident.' But the group temporarily shut down all its sites on June 4, in an apparent acknowledgment that it had faced challenges in distributing aid, before reopening them the following day. The Israeli military has offered mixed messages. It has both denied shooting civilians in the vicinity of the distribution site and acknowledged firing warning shots toward 'suspects' who were approaching soldiers nearby. It was still unclear whether there were other sources of gunfire in the area. Asked who shot the Palestinians on June 1, a military spokesperson referred to an earlier statement that did not answer the question. A UN briefing paper circulated before the foundation's initiative was launched last week warned of 'overcrowded distribution sites' and said that Israeli forces or American contractors might 'use force to control crowds.' The memo also cautioned about the potential for 'organised and opportunistic looting' near the hubs. Mr Jalal al-Homs, 35, said he left a tent in southern Gaza where his family was sheltering around 1.30am on June 1. Accompanied by his brother, he walked for two hours through darkness to Rafah, where he joined throngs of people trying to secure food. Israeli military vehicles, he said, could be seen in the distance, and drones could be heard hovering in the sky. It was Mr al-Homs' fourth attempt this week to get a box, he said. On previous trips, he said, all the aid had been taken by the time he made it into the distribution site. Mr Al-Homs said people were trying to push their way to the front of the crowd before the shooting began around 4.30am. 'It felt like it came from all over,' he said. His brother was shot in the leg, he said, and taken to a hospital, where he underwent surgery. Despite the danger, Mr al-Homs said, he had few options other than returning to the distribution site so that he could feed his two sons and two daughters. 'This system isn't just at all – it requires me risking my life for food,' he said. NYTIMES Join ST's Telegram channel and get the latest breaking news delivered to you.
Straits Times
a day ago
- Straits Times
Used in Covid-19 shots, mRNA may help rid the body of HIV
The new study describes the use of mRNA as a tool to flush HIV out of its hiding places. PHOTO: UNSPLASH Used in Covid-19 shots, mRNA may help rid the body of HIV NEW YORK - The technology that powered Covid-19 vaccines may also lead scientists to a cure for HIV. Using mRNA, Australian researchers said they were able to trick the virus to come out of hiding, a crucial step in ridding the body of it entirely. The research, published last week in Nature Communications, is still preliminary and so far has been shown to be successful only in a lab. But it suggests that mRNA has potential far beyond its use in vaccines as a means to deliver therapies against stubborn adversaries. Short for messenger RNA, mRNA is a set of instructions for a gene. In the case of Covid-19 vaccines, the instructions were for a piece of the coronavirus. In the new study, they are for molecules key to targeting HIV. Dr Sharon Lewin, director of the Doherty Institute at the University of Melbourne, who led the study, called mRNA a 'miraculous' tool 'to deliver things that you want into places that were not possible before.' Vaccines deploying mRNA instruct the body to produce a fragment of the virus, which then sets off the body's immune response. In the United States, the shots were initially hailed for turning back the pandemic, then viewed by some with suspicion and fear. Some officials, including Health Secretary Robert F. Kennedy Jr, have falsely said that they are highly dangerous and even deadly. Last week, the Department of Health and Human Services sought to limit the vaccine's availability to pregnant women, children and healthy younger adults. The administration also cancelled a nearly US$600 million (S$773.72 million) contract with the drugmaker Moderna to develop an mRNA shot for humans against bird flu. 'The fear right now is not rational,' Dr Lewin said, adding that 'mRNA vaccines have been given to millions of people around the world, so we have a very good understanding of their risks.' The new study describes the use of mRNA as a tool to flush HIV out of its hiding places. Other uses could involve providing proteins missing from those with certain diseases or correcting genetic errors. Dr Frauke Muecksch, a virologist at Heidelberg University in Germany who was not involved in the work, called mRNA a 'promising, absolutely powerful technology.' Although most people may have only heard of mRNA's use in science during the pandemic, scientists have been working with it for more than 20 years, she said. 'I think it's not just therapeutically very powerful, but also for basic science, for research, it opens up a lot of avenues,' she added. Potent antiretroviral drugs can now control HIV, suppressing it to undetectable levels. Still, minute amounts of the virus lie dormant in so-called reservoirs, waiting for an opportunity to resurge. A cure for HIV would involve ferreting out all of this virus and destroying it, a strategy that has been called 'shock and kill.' A significant hurdle is that the virus lies dormant in a particular type of immune cell, called a resting CD4 cell. Because these cells are inactive, they tend to be unresponsive to drugs. The few drugs scientists have previously used to rouse the virus in these cells were not specific to HIV and had unwanted side effects. 'It's fair to say the field's been a little bit stuck,' said Dr Brad Jones, a viral immunologist at Weill Cornell Medicine who was not involved in the latest research. In 2022, Dr Jones and his colleagues found that the immune boost from the mRNA vaccines awakened latent HIV in people living with the virus. (Other research has shown that mRNA vaccines also activated dormant viruses including Epstein Barr.) 'You get just a little bit of a gentle nudge with some of these vaccines, and it's enough to coax some of these latent viruses out so they can be killed,' Dr Jones said. Dr Lewin and her colleagues had for years experimented with other ways to activate HIV, but had no luck in resting cells. Seeing the success of the Covid-19 vaccines, which used lipid nanoparticles – tiny spheres of fat – containing mRNA, her team tested similar particles. They used the particles to deliver two different sets of molecules: Tat, which is adept at switching HIV on, and CRISPR, a tool that can 'edit' genes. The researchers showed that in resting immune cells from people living with HIV, the approach coaxed the virus out of dormancy. 'It's very, very hard to deal with these cells, so I think this really targeting the right population of cells is what makes this paper special,' Dr Muecksch said. It's unclear whether the new approach can successfully awaken all of the dormant HIV in the body, and what side effects it might produce. Dr Lewin said that 'mRNA will almost certainly have some adverse effects, as every drug does, but we will investigate that systematically, as we do for any new drug.' In this case, she said, side effects may be more acceptable to people living with HIV than having to take medications for the rest of their lives. The researchers plan to test the method in HIV-infected animals next, before moving into clinical trials. NYTIMES Join ST's Telegram channel and get the latest breaking news delivered to you.
